The Association for Accessible Medicines' new president and CEO, Dan Leonard, goes behind the mic to talk about the pathway to his new gig, the promise of biosimilars, what the 2020 election means for the generic drug industry, and why COVID-19 has underscored the public health impact of generic drugs.  <a href="https://twitter.com/dleonard_dc">Keep up with Dan on Twitter</a>.

The Association for Accessible Medicines' new president and CEO, Dan Leonard, goes behind the mic to talk about the pathway to his new gig, the promise of biosimilars, what the 2020 election means for the generic drug industry, and why COVID-19 has underscored the public health impact of generic drugs. Keep up with Dan on Twitter.

The Association for Accessible Medicines' new president and CEO, Dan Leonard, goes behind the mic to talk about the pathway to his new gig, the promise of biosimilars, what the 2020 election means for the generic drug industry, and why COVID-19 has underscored the public health impact of generic drugs.&nbsp; <a href="https://twitter.com/dleonard_dc" rel="noopener noreferrer">Keep up with Dan on Twitter</a>.&nbsp;

S2 E5: AAM's Dan Leonard on What's Next for Generic Drugs and Biosimilars

W2O Group's regular look at the value and access conversation in health care, with Brian Reid, the founder of the W2O Value+Access Communications Practice.

Share S2 E5: AAM's Dan Leonard on What's Next for Generic Drugs and Biosimilars

Sign up to save your podcasts

S2 E5: AAM's Dan Leonard on What's Next for Generic Drugs and Biosimilars

S2 E5: AAM's Dan Leonard on What's Next for Generic Drugs and Biosimilars